DSPE-RGD Lipid A87295 (Previously 870295) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-(cysarginylglycylaspartate-maleimidomethyl)cyclohexane-carboxamide] (sodium salt)
DSPE is a fully saturated phospholipid consisting of 18 carbon atoms, frequently employed in the creation of liposomes. Phospholipid Polyethylene Glycol RGD (DSPE-PEG-RGD) finds versatile applications in micelles and vesicles, functioning for both passive and active targeting, along with drug delivery. The integration of Polyethylene Glycol (PEG) with DSPE renders it hydrophilic, facilitating applications in drug delivery, gene transfection, and biomolecular modification. The introduction of PEG to the phospholipid notably enhances the durability and circulation lifespan of encapsulated medications.
DSPE-RGD lipid represents a lipid compound suitable for incorporation into liposomes—microscopic, spherical structures composed of a double layer of lipids. DSPE-RGD introduces a more advanced iteration, having undergone modification with the RGD peptide sequence.
The RGD peptide sequence, an acronym for arginine-glycine-aspartic acid, is a short string of amino acids with the capacity to attach to integrin receptors situated on cell surfaces. These integrin receptors are present in various cell types, including cancer cells and those lining blood vessels.
Importantly, DSPE-RGD lipid is biocompatible, thereby minimizing the likelihood of triggering immune reactions or significant bodily toxicity.
Research has demonstrated that DSPE-RGD enhances the concentration of drugs within tumor tissue, thereby enhancing the efficacy of chemotherapy and other cancer therapies. Additionally, it has been observed to diminish the adverse effects of these treatments on normal cells. Through the precisely targeted mechanism of DSPE-RGD liposomes, drugs can be selectively transported to tumor tissue, thereby mitigating the potential harm to healthy cells.
DSPE-RGD holds promise in yet another field: addressing cardiovascular illnesses. The RGD peptide sequence not only has the potential to zero in on integrin receptors present on blood vessel cells' surfaces but also presents the opportunity for precise drug delivery to afflicted vessels. This targeted approach could foster healing and decrease the likelihood of complications such as heart attacks or strokes.
Moreover, DSPE-RGD could extend its usefulness to the realm of inflammatory conditions, including rheumatoid arthritis. As inflammatory cells also exhibit integrin receptors, they become a feasible target for DSPE-RGD liposomes. By conveying anti-inflammatory agents directly to these cells, DSPE-RGD could contribute to diminishing inflammation and alleviating associated symptoms.
